SLC9C1 and heart failure: Furthermore, preclinical studies with known NHE inhibitors have clearly shown reductions in the development of hypertrophy and heart failure [13, 14], which support NHE inhibition and its consequential [Na+]c-lowering as a potential class effect of SGLT2i to combat heart failure.